Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Bristol-Myers Squibb Co (NYSE: BMY) closed the day trading at $48.46 up 1.17% from the previous closing price of $47.90. In other words, the price has increased by $1.17 from its previous closing price. On the day, 18.44 million shares were traded. BMY stock price reached its highest trading level at $48.86 during the session, while it also had its lowest trading level at $47.95.
Ratios:
For a better understanding of BMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.54. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.28. In the meantime, Its Debt-to-Equity ratio is 2.95 whereas as Long-Term Debt/Eq ratio is at 2.73.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Neutral rating and target price of $55.
Jefferies Upgraded its Hold to Buy on December 16, 2024, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’25 when BOERNER CHRISTOPHER S. bought 2,000 shares for $55.05 per share. The transaction valued at 110,096 led to the insider holds 104,626 shares of the business.
Hirawat Samit bought 1,823 shares of BMY for $100,000 on Feb 14 ’25. The EVP,Chief Med.Offr.,Drug Dev. now owns 63,932 shares after completing the transaction at $54.84 per share. On Nov 04 ’24, another insider, Holzer Phil M, who serves as the SVP and Controller of the company, sold 700 shares for $55.62 each. As a result, the insider received 38,930 and left with 11,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 100246290432 and an Enterprise Value of 138168008704. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.19, and their Forward P/E ratio for the next fiscal year is 8.02. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.07 while its Price-to-Book (P/B) ratio in mrq is 5.67. Its current Enterprise Value per Revenue stands at 2.9 whereas that against EBITDA is 7.36.
Stock Price History:
The Beta on a monthly basis for BMY is 0.42, which has changed by 0.1028676 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, BMY has reached a high of $63.33, while it has fallen to a 52-week low of $39.35. The 50-Day Moving Average of the stock is -14.06%, while the 200-Day Moving Average is calculated to be -10.09%.
Shares Statistics:
Over the past 3-months, BMY traded about 13.29M shares per day on average, while over the past 10 days, BMY traded about 16243220 shares per day. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 79.85% stake in the company. Shares short for BMY as of 1744675200 were 30034861 with a Short Ratio of 2.26, compared to 1741910400 on 37010551. Therefore, it implies a Short% of Shares Outstanding of 30034861 and a Short% of Float of 1.48.
Dividends & Splits
BMY’s forward annual dividend rate is 2.44, up from 2.44 a year ago. Against a Trailing Annual Dividend Yield of 0.050939456The stock’s 5-year Average Dividend Yield is 3.52.
